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Histone ModiﬁcationsClusterin (CLU) is an important glycoprotein involved in various cellular functions. Different reports have
mentioned that the two isoforms of CLU; secretary (sCLU) and nuclear (nCLU) have opposite (paradoxical)
roles in cancer development. sCLU provides pro-survival signal, whereas nCLU is involved in pro-apoptotic
signaling. However, the molecular mechanism of CLU gene regulation is not clear as of yet. We hypothesize
that CLU gene is regulated by DNA methylation and histone modiﬁcations and clusterin plays an important
role in colon cancer. To evaluate the hypothesis, we investigated CLU expression in colon cancer tissues and
DNA methylation and histone modiﬁcation status of CLU gene promoter. It is apparent from immonohistology
data that both benign and cancerous (primary and metastasis) formalin ﬁxed parafﬁn embedded (FFPE) tissue
samples exhibit CLU expression. However and interestingly only noncancerous tissue samples show nCLU
expression. Ectopic expression of nCLU either by epigenetic modulators or by nCLU transfection is responsible
for colon cancer cell death. To clarify the molecular mechanisms for regulation of expression of CLU isoforms,
we have analyzed DNA methylation and histone modiﬁcations, such as histone H3K9me3, H3K27me3,
H3K4me3, and H3K9AcS10P patterns around the CLU promoter. There is no remarkable change in the DNA
methylation status upon treatment of the cells by AZA, TSA and SAM. Our ﬁndings clearly show that promoter
histone H3K9me3 and H3K27me3 marks are elevated in comparison to H3K4me3 and H3K9AcS10P marks in
colon cancer cell lines.
© 2015 Elsevier B.V. All rights reserved.1. Introduction
Clusterin (CLU) is a heterodimeric disulﬁde-linked glycoprotein. It is
expressed in a wide variety of tissues in human and is involved in
numerous physiological processes, including cell cycle regulation, cell
adhesion, DNA repair, tissue remodeling, lipid transportation, mem-
brane recycling and apoptotic cell death [1,2]. CLU has two different
isoforms, external secretary CLU (sCLU) and nuclear CLU (nCLU). sCLU
is a heterodimeric glycoprotein and relays pro-survival signal during
stress-induced injury, such as heat shock [3,4]. The nuclear residing
nCLU [2,5,6] is an uncleaved, nonglycosylated, and disulﬁde-linked
isoform which operates a death induced signal [6]. sCLU is synthesized
by translation from the ﬁrst AUG codon of full-length CLU mRNA. This
part synthesizes the initial leader peptide that targeted to the endoplas-
mic reticulum. This 60-kDa pre-sCLU protein is further glycosylated and
proteolytically cleaved into β- and α-subunits, held together by ﬁve di-
sulﬁde bonds. Themature secretory (sCLU) protein is ultimately 80-kDa91 6612462681.
oo.com (S.K. Patra).protein. nCLU is synthesized by alternative splicing from second AUG
codon located in 152 position. nCLU lacks a leader peptide and thus
skipping α/β cleavage and glycosylation [7,8]. Over the recent years it
has become interestingly clear that aberrant expression of CLU contrib-
utes to different cellular and physiological dysfunctions. Increased CLU
expression has been linked with several human cancers, including
colorectal cancer, the third leading cause of cancer related death in the
world. Increasing CLU expression leads to cancer cell survival by
inhibiting apoptosis through shielding Bax activation in mitochondria
[9]. CLU overexpression in stage II colorectal cancer is associated with
drug resistance and cancer cell survival [10]. The prevailing view is
that — during cancer development, sCLU expression is increased while
nCLU expression is decreased. Moreover, the expression of sCLU in
metastasis stage is higher than primary cancer stage [11]. The enhanced
sCLU expression in metastasis progression during hepatocellular
carcinoma [12], breast [13] and colon cancer is associated with
p38MAPK phosphorylation andMMP-9 activationmediated cell surviv-
al [14]. Overexpression of nCLU has been reported to induce G2/M
phase arrest and caspase-dependent apoptosis in prostate [15] and
colon [16] cancers. Although functions of the CLU isoforms are clear
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regulation in cancer, especially, that in colon cancer is unknown. We
hypothesize that epigenetic modiﬁcations have a signiﬁcant impact in
CLU gene regulation and expression during colon cancer progression.
To explore how expression of CLU is epigenetically modulated
in colon cancer we have investigated expression pattern of CLU
protein isoforms, DNAmethylation and histone modiﬁcation pattern
of the nucleosomes encompassing the CLU promoter. We report
here that treatment of cells with epigenetic modulators including,
5-aza-2′-deoxycytidine (AZA), a well established DNMT inhibitor
[17], S-adenosylmethionine (SAM), methyl group donor [18],
trichostatin A (TSA), a well established HDAC inhibitor [19] and sul-
foraphane (SFN), a newly developed HDAC inhibitor [20,21] can
change the expression level of sCLU and nCLU differentially in
colon cancer cell lines. Chromatin condensation, DNA break analysis
and autophagic vacuole assessment make this clear that elevated
nCLU expression by treatment of AZA, TSA and SFN is associated
with increase cell death. This is further conﬁrmed by nCLU transfec-
tion and overexpression induced cell death in colon cancer cell line.
Promoter CpG island (CGI) methylation analysis of nCLU gene clearly
dictated that there was no signiﬁcant change of DNA methylation
density; and histone modiﬁcation analysis has demonstrated that
nCLU gene regulation in colon cancer is controlled by occupancy/en-
richment of histone 3 lysine 9 trimethylation (H3K9me3), histone 3
lysine 4 trimethylation (H3K4me3), histone 3 lysine 9 acetylationFig. 1. Clusterin expression analysis in colon cancer tissues. Immunohistochemical analysis
sue sample shows sCLU and nCLU expression (arrow). [B] is primary and [C, D] are metas
show higher level of sCLU expression than [B] (arrow). [AII] shows the expression of sC
metastasis cancer cell. Scale bar = 20 (AI, BI, CI, DI) and 40 μm (AII, BII, CII, DII).and serine 10 phosphorylation (H3K9AcS10P) in the promoter
region. Our results establish that promoter methylation is not re-
sponsible for nCLU down-regulation, rather histone H3K9me3 en-
richment might be a more deciding factor for down-regulation of
nCLU. When enrichment of histone H3K4me3 or H3K9AcS10P is
very high the nCLU gene is activated and high expression triggers
cell death.
2. Results
2.1. Expression proﬁle of CLU in different stages of colon cancer
The role of clusterin in tumor growth and progression remains
unclear. Previous reports show that CLU is having both tumor suppres-
sor and stage II speciﬁc cancer promoter role in multiple cancers. This
paradox may be due to the heterogeneity in the expression of CLU
during carcinogenesis. We analyzed CLU expression in 55 FFPE tissue
blocks of colon cancer (CCR) samples by immunohistochemistry.
Among FFPE colon tissue samples, there were 4 non-carcinogenic
tumors, 43 primary stage and 8 metastasis stage tissue samples. In
consistency with earlier reports, all colon samples exhibited CLU
expression (Fig. 1A). But metastatic cells appear to be very rich in
cytoplasmic CLU expression than the primary stage cells. In non-
carcinogenic colon tumor tissue samples, CLU expression is observed
in both cytoplasmic (Fig. 1AII) and nuclear (Fig. 1AII) compartments.of the CLU expression (400× and 200× magniﬁcation): [A] is non cancerous FFPE tis-
tasis tissue sample. Both shows sCLU expression (arrow). Metastases samples [C, D]
LU and nCLU in non-cancerous FFPE tissue sample. [CII] showed sCLU expression in
Table 1
CLU expression in FFPE and post-operated colon cancer tissue samples.
Clinical colon cancer samples Number of
samples




Absence of CLU expression
in RNA/protein level (%)
FFPE tissue sample (analyzed for protein
level CLU expression)
55 ≤70 Metastasis stage/8 100 (8 samples) –
Primary stage/43 81.4 (35 samples) 18.6 (12 samples)
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out of 43) (Fig. 1B, Table 1) shows low CLU expression. However, all
the metastasis stage tissue samples, 8 samples out of 8 (100%) exhibit
high CLU expression (Fig. 1C, D, Table 1). Data from immunohistochem-
istry experiments clariﬁes that the expressed CLU in cancer tissue sam-
ples are sCLU (Fig. 1-CII). These analyses are in good agreement with
vital dual role of CLU isoforms in colon cancer (Fig. 1B, C, D).
To explore the paradox of CLU expression and function in colon
cancer, we have applied epigenetic tools. Firstly, we have tested the
effect of epigenetic drugs on CLU protein expression, cellular morphol-
ogy, DNA damage and chromatin condensation.2.2. Effect of epigenetic modulators in CLU expression
Epigenetic modulators change epigenetic marks/landscape globally/
genome wide and gene speciﬁcally and thus alter gene expression.
Changes in gene expression after epigenetic modulators treatment in
colon cancer cell line indicates that the gene is directly or indirectly
controlled by epigenetic modiﬁcations. We hypothesize that in colon
cancer, the epigenetic modulators may change the DNA methylation
or histone methylation and acetylation of chromatin around CLU gene
promoter. To verify our hypothesis we had executed the following
experiments.2.3. Role of DNMT inhibitor, AZA, in CLU transcript
AZA decreases themethylation level by inhibiting the DNMTs. Colon
[17] and breast [22] cancers are inhibited by passive DNA demethyla-
tion after AZA treatment. We treated the colon cancer cell lines with
AZA to observe the change in CLU expression level and tried to correlate
CLU expression with reduced DNA methylation level. HCT15 and
COLO205 cells were treated with 25 and 19 μM AZA, respectively.
These are the IC50 values of the drug for respective cell lines (data not
shown). After AZA treatment, expression of CLU at transcriptional
level is found to be upregulated by 3.81 folds and 3.17 folds in HCT-15
and COLO205 respectively (Fig. 2).Fig. 2.CLUmRNA analyses by cell culture after drug treatment. AZA, SAM, TSA and SFN
treatment increased CLUmRNA level in both cell lines. CLUmRNA level wasmeasured
by reverse transcription-PCR. The CLU level in DMSO treated cells for AZA, TSA and
SFN and without DMSO treated cells for SAM was normalized to 1 (n = 3 indepen-
dent experiments mean ± S.D.). P b 0.05.2.4. Effect of histone deacetylase inhibitors TSA and SFN in CLU transcript
Cancer progression is controlled by TSA and SFN treatment in differ-
ent cancers, including colon [19,23,24], and breast cancer [25]. Both TSA
and SFN are HDAC inhibitors and we tried to ﬁnd out the impact of
HDAC inhibitor treatment on CLU expression. HCT15 and COLO205
cells were treated with 180 and 160 nM TSA and 18 and 17 μM SFN
respectively. Increased CLU expression is observed after TSA and SFN
treatment. Folds of increase in CLU mRNA levels are 25.56 in HCT15
and 6.29 in COLO205 after TSA treatment, whereas SFN treatment
increases CLU expression by 8.35 folds in HCT15 and 6.50 folds in
COLO205 (Fig. 2) which all are remarkably very high.
2.5. Effect of S-adenosylmethionine (SAM) in CLU transcript
Previous report implicated the involvement of SAM affecting C-myc
and H-Ras genes in colon cancer [18,26].We are ﬁrst to report that SAM
treatment also changes CLU expression in metastatic colon cancer cell
lines. 20 μM SAM treatment increases CLU expression by 2.52 folds in
HCT15 and 4.19 folds in COLO205 (P b 0.05) (Fig. 2).
2.6. Epigenetic modulators accentuate sCLU and nCLU overexpression
Immunocytochemistry and western blot analysis have revealed that
not only at mRNA level, but also at protein level CLU expression is
increased after treatment of cells for more than 24 h with epigenetic
modulators (Fig. 3, panels I and II). All four modulators increase sCLU
protein expression in both cell lines; interestingly, however, it has
been found that AZA, TSA and SFN increase nCLU expression (Fig. 4,
panel I A, B and panel II A, B). Relative folds of nCLU protein expression
were 1.13, 0.74, 1.68 and 1.19 in HCT15 and 1.67, 0.26, 4.34, and 4.44 in
COLO205 after treatment with AZA, SAM, TSA, and SFN respectively.
Relative fold of sCLU protein expression was 1.13, 1.11, 1.4, and 1.23
in HCT15 and 1.68, 2.14, 3.44, and 4.03 in COLO205 after treatment
with AZA, SAM, TSA, and SFN respectively (Fig. 4, panel I B, Table 2).
As discussed above, AZA is a potent inhibitor of DNAmethyltransfer-
ase enzymes, hence, a hypomethylation agent. Keeping this fact inmind
we proceededwith our experiments to analyze whether the expression
of sCLU and nCLU changes after prolong treatment with AZA for four
days at different doses in both HCT-15 andCOLO-205 cell lines. Interest-
ingly, our results indicate that at lower dose of AZA i.e., at 1.5 μMthere is
almost no change in both nCLU as well as sCLU expression. However,
with increasing dose of AZA from 3 μM to subsequently at IC50 concen-
tration 5 μM for COLO205 and 7 μM for HCT15 for 4 days we noticed
upregulation in expression of both nCLU and sCLU. After treatment
with AZA for 4 days nCLU expression was upregulated to 2.06 and
2.49 folds in 3 μM and 7 μM treated HCT15 cells; and 1.17 and 2.04-
fold increase in 3 μM and 5 μM AZA treated COLO205 cells (Fig. 5).
This result is in quite good stand with the changes in expression of
nCLU and sCLU after 24 h of AZA treatment.
2.7. Effect of cytotoxic reagent cytosine arabinoside (Ara-C) on
CLU expression
To ﬁnd out whether the induction of nCLU expression after treat-
ment with epigenetic modulators is solely due to rise in cytotoxicity
effect or due to factors regulated by drugs including epigenetic factors,
Fig. 3. CLU protein analyses by cell culture after drug treatment. Immunocytochemistry (400×) of CLU showed that in [I] HCT15 and [II] COLO205 cell CLU expression (arrow) increased
after treatment with epigenetic modulators with respect to speciﬁc control (without treatment) cells. Only adherent cell of COLO205 was analyzed. Scale bar = 40 μm.
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well known cytotoxic inducer. Our results indicate that treatment of
both cell lines with Ara-C produces IC50 value at 21 μM for HCT15 and
20 μM for COLO205 and there is little upregulation in both sCLU and
nCLU. The values are 1.85 and 1.20 folds for sCLU; and 1.52 and 1.27
folds for nCLU in HCT15 and COLO205 cell lines respectively (Fig. 6).Fig. 4.Western blot analyses of CLU protein isoforms. (Panel [I-A]) HCT15 cell lysateswere subje
loading. Panel [I-B] is the graphical representation of relative expression level of sCLU and nCLU
western blotting with antibody speciﬁc for CLU. Anti-β-actin was used to conﬁrm equal loadin
protein after treatment in COLO205 cell. Relative protein expression level was analyzed by Imag
without DMSO treated cells for SAM were normalized to 1 (n = 3 independent experiments, mHowever, the increase in nCLU expression after treatment with AZA,
TSA and SFN is much higher than that of Ara-C treatment. This clearly
indicates that the change in nCLU expression after treatment with epi-
genetic modulators was not solely due to cytotoxic stress, rather was
due to the regulation of epigenetic factors differentially. Of notice, in
the case of stress induced gene regulation theremight also be epigeneticcted towestern blottingwith antibody speciﬁc for CLU. β-Actinwas used to conﬁrm equal
protein after treatment inHCT15 cell. (Panel [II-A]) COLO205 cell lysateswere subjected to
g. Panel [I-B] is the graphical representation of relative expression level of sCLU and nCLU
eJ software and the nCLU and sCLU levels in DMSO treated cells for AZA, TSA and SFN and
ean ± S.D.). P b 0.05.
Table 2
Outcomes of different drug treatment experiments in colon cancer cell lines.
Name of the
experiment
Treatment of HCT-15 (with
respect to untreated cells in
increasing order)
Treatment of COLO-205
(with respect to untreated
cells in increasing order)
sCLU expression SAM b AZA b TSA b SFN SAM b AZA b TSA b SFN
nCLU expression SFN b TSA b AZA b SAM SFN b TSA b AZA b SAM
Chromatin
condensation




cells b SFN = TSA = AZA
SAM b Untreated
cells b SFN = TSA = AZA
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expression of CLU after treatment with IC50 values of AZA, TSA and
SFN is higher than the expression of CLU after treatment with IC50 of
Ara-C, indicating that the changes in expression of CLU are mainly due
to the epigenetic changes induced by the treatment of above drugs
and not due to cytotoxicity caused by them.2.8. Effect of epigenetic modulator arbitrates CLU overexpression and
chromatin condensation
During apoptosis, chromatin changes into an inert and highly
condensed form, which is fragmented and packaged into apoptotic
bodies [27]. Highly stained nuclei with Hoechst 33342 can be compared
to apoptotic cells. After 24 h treatment of HCT15 and COLO205with fourFig. 5.Western blot analyses of CLU protein isoform expression after treatedwith different conc
and panel [II]) COLO205 cell lysates were subjected to western blotting with antibody speciﬁc
representation of relative expression level of sCLU and nCLU proteins after treatment in HCT15
the nCLU and sCLU levels in DMSO treated cells were normalized to 1 (n = 3 independent expepigenetic modulators, independently at speciﬁed concentrations, cells
were stained with Hoechst 33342 to observe nuclear morphology and
condensed chromatins. Earlier, numerous studies have described the re-
lationship between apoptosis and chromatin condensation. In AZA,
SAM, TSA and SFN treated cells, percentage of condensed nuclei was
15.61%, 2.95%, 27.19%, and 30.97% in HCT15 (Fig. 7, panels I and III)
and 5.28%, 2.16%, 63.19%, and 58.88% in COLO205 (Fig. 7, panels I and
III) respectively, whereas control and DMSO treated control showed
1.03%, and 1.63% in HCT15 (Fig. 7, panel I and III) and 0.97%, 1.67% in
COLO205 respectively (Fig. 7, panels II and III). The result indicates
that AZA, TSA and SFN treated HCT15 and COLO205 cells exhibit highly
stained condensed bright nucleus,while the untreated cells exhibit very
less condensed chromatin. In contrast, the percentage of condensed
nuclei after SAM treatment was found to be very low, 2.95% in HCT15
and 2.26% in COLO205, which approximate the control (Fig. 7, panels I,
II and III, Table 2).2.9. nCLU increases the autophagy vacuole formation
Increased autophagy formations induce cell death in cancer cell lines
[28]. Representativemicrophotographs of autophagy vacuole formation
showing the effect of AZA, TSA and SAM induced enhanced vacuoles
formation are seen in Fig. 8. Autophagy formation was increased in
TSA, SFN and AZA treated cells. Nuclear condensation and autophagy
vacuole formation suggested that treatment with AZA, TSA and SFN
induces cell death and reduced aggressiveness in HCT15 and COLO205
in different proportions. We hypothesized that increase of nCLUentrations of AZA: Different concentrations of AZA treated and untreated. (Panel [I] HCT15
for CLU and β-actin. β-Actin was used to conﬁrm equal loading. Panel [III] is the graphical
and COLO205 cells. Relative protein expression level was analyzed by ImageJ software and
eriments, mean ± S.D.). P b 0.05.
Fig. 6. Effect of Ara-C in sCLU and nCLU expression in colon cancer cell lines: (Panel [I]) cell viability analysis curve of Ara-C in colon cancer cell lines. IC50 concentration was 21 μM for
HCT15 and 20 μM for COLO205. At 5 μM concentration both cell line exhibit 80% to 85% cell viability. Effect of Ara-C at low and higher IC50 concentrations in CLU isoform expression
was observed. sCLU and nCLU expression in (panel [II A]) 5 μMand 21 μM(IC50) Ara-C treatedHCT15 and (panel [III A]) 5 μMand20 μM(IC50) treated COLO205were analyzedbywestern
blotting. The cell lines treatedwith IC50 concentrationwere exhibit highest nCLU expression in both cell lines. Panels [II B] and [III B] are the graphical representation of relative expression
level of sCLU and nCLUprotein after treatment inHCT15 and COLO205 cell respectively. Relative protein expression level was analyzed by ImageJ software and the nCLU and sCLU levels in
DMSO treated cells were normalized to 1 (n = 3 independent experiments, mean ± S.D.). P b 0.05.
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cancer cell lines.2.10. nCLU, not sCLU, overexpression inhibits growth of HCT15 cells
To further conﬁrm the hypothesis that nCLU induce cell death,
HCT15 cells were transfected with pIRES, pIRES–sCLU and pIRES–
nCLU. pIRES–nCLU transfected cells exhibited higher nCLU expres-
sion (Fig. 9, panel I A, B). pIRES–nCLU–HCT15 was analyzed for
the autophagy formation. Results showed that autophagy vacuole
formation and chromatin condensation increased in pIRES–nCLU–
HCT15 cells rather than pIRES–HCT15 cells (Fig. 9 panels II and III).
However sCLU transfection (Fig. 9, panel I C, D) was not responsible
for increase autophagy vacuole formation and chromatin condensa-
tion (Fig. 9 panels II and III).2.11. Analysis of CpG island methylation in the CLU gene promoter
While sCLU had a basal expression, it is upregulated after treatment
with AZA, SAM, TSA and SFN; however, nCLU had no basal expression,
it is signiﬁcantly upregulated in AZA, TSA and SFN treated colon cancer
cells. So it can be considered that there are different molecular mecha-
nisms, signaling pathways, or epigenetic modiﬁcations which control
different CLU isoform expressions. We have examined the methylation
pattern in CLUpromoter region by bioinformatics and bisulﬁte sequenc-
ing. To explore that the regulation of clusterin expression is indepen-
dent of DNA methylation, we analyzed the data submitted from
cancer genome atlas using MethHC database. This database has stored
information regarding the correlation between expression of genes
and DNA methylation % at promoter region. Data mining from above
database indicates a negative correlation value. The−0.03 value repre-
sents that, % of DNA methylation at promoter region and clusterin
Fig. 7. Chromatin condensation analyses in cells after drug treatment. (Panel [I]) HCT15 cells were stained with Hoechst 33342 after treatment with AZA, TSA, SFN, and SAM for 24 h.
The representative images (200×) of Hoechst 33342 stained nuclei (arrow) are shown. (Panel [II]) Percentage of condensed nuclei is represented graphically (n= 3 independent exper-
iments, mean ± S.D.). P b 0.05. [6000 cells in HCT15 and 1000 cells in COLO205 were analyzed by a Epi-ﬂuorescent Microscope (Olympus IX71).] Scale bar = 20 μm.
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P value of such correlation is highly signiﬁcant indicating that the
clusterin expression is independent of DNA methylation at promoter
region (Fig. 10)
Promoter region of CLU gene was retrieved from http://www.
genomatix.de/ software and evaluated by UCSC genome browser
(Fig. 10, panel I). Bisulﬁte primers were designed using a meth-primer
designing tool (http://www.urogene.org/methprimer/). Upstream
region of CLUgene (Chr8: 27,472,279–27,472,691 413 bp)was analyzed
by bisulﬁte sequencing (Fig. 10, panel I: A, B, C). A total of 20 CpG sites
were analyzed by bisulﬁte sequencing (Fig. 10, panel I: D). In HCT15
and COLO205 untreated cells, a total of 19 sites were found to be
unmethylated (Fig. 10, panel II: A, B). There was not a single methyla-
tion in the CLU promoter CGI from both the cell lines after treatment
with AZA, TSA and SFN (Fig. 10, panel II: A, B). In the case of SAM treated
colon cancer cells, methylated CpG sites are increased (Fig. 10, panel IIA
and II B). In SAM treated cells, 4 CpG sites are found to be methylated,
i.e., 1st, 6th, 14th and 15th in HCT15 whereas 3rd, 6th, 9th and 12thin COLO205 (Fig. 10, panel II: A, B). However, it was not sufﬁcient to
repress the CLU gene.
2.12. Analysis of histone modiﬁcations in the CLU gene promoter in HCT15,
COLO205, TSA-HCT15 and LNCaP cells
Since there was no signiﬁcant promoter DNA methylation for
controlling CLU expression we assumed that histone modulation is
involved. Accordingly we had carried out ChIP analysis for visualizing
histone tail modiﬁcations. We performed ChIP analysis in HCT15 and
COLO205 to identify the abundance of H3K4me2, H3K4me3,
H3K9me3, H3K27me3 and H3K9AcS10P in the CLU promoter CGI
region. H3K4me3 and H3K9AcS10 are experimentally well established
active histone marks [29–31]. ChIP-primer ampliﬁed region (chr8:
27,472,302–27,472,158, 198 bp) was similar to the ampliﬁed region
which was detected for bisulphite sequencing (Fig. 11, panel I). From
PCR analysis, the presence of H3K4me3 in the CGI promoter region of
CLU was evident (Fig. 11, panel II: A, B). This was followed by RT-PCR
Fig. 8. Analyses of drug induced autophagy vacuoles. After 24 hour treatment with AZA, SAM, TSA and SFN cells were stained with acridine orange and examined under a Epi-ﬂuorescent
Microscope (Olympus IX71). AZA, TSA and SFN treatment promoted autophagosome vacuole formation (indicated by red staining and white arrow) (n = 3 independent experiments).
Scale bar = 20 μm.
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high level of H3K9me3 and H3K27me3 enrichment in both the cell
lines. The relative presence of H3K9me3 was 0.67 and 0.18 folds
whereas of H3K27me3 mark was 1.55 and 0.84 folds in HCT15 and
COLO205 respectively (Fig. 11, panel II A, and B). But the level of
H3K4me3 and H3K9AcS10P occupancy was 0.12, and 0.03 folds in
HCT15 and 0.03, and 0.04 folds in COLO205 cell which is very much
lower than H3K9me3 and H3K27me3 marks in both cell lines (Fig. 11,
panel II B).
The apparent levels of H3K9me3, H3K27me3, H3K4me3 and
H3K9AcS10P enrichment in the CLU promoter region of untreated
cells indicate that perhaps H3K9me3 and H3K27me3 enrichment is
the cause of relatively very low CLU expression in colon cancer cell
lines. Previous research depicted that the CLU promoter region of
prostate cancer LNCaP cell lines was methylated [32] and nCLU down-
regulation is associated with prostate cancer survival [33]. Our above
results conﬁrmed that in COLO205 and HCT15 cell lines, CLU promoter
region was unmethylated and ChIP analysis shows that increased level
of H3K9me3 was associated with nCLU down-regulation. To conﬁrm
the availability of H3K9me3 and H3K27me3 around DNA methylated
CLU promoter, we proceeded with LNCaP cell line analysis. ChIP result
veriﬁed the H3K9me3 and H3K27me3 enrichment in CLU promoterregion in LNCaP. The level of H3K9me3, H3K4me3 and H3K9AcS10P
was 1.69, 0.38 and 0.12 folds respectively in CLU promoter (Fig. 12).
To further strengthen our hypothesis, we also have analyzed
H3K9me3, H3K27me3, H3K4me3 and H3K9AcS10P modiﬁcation of
CLU promoter region after treatment of HCT15 cells with TSA; as we
have noticed the highest level of CLU expression after TSA treatment
(compare with Fig. 2). Surprisingly, however, very satisfactorily it is ap-
parent from the results that H3K4me3 andH3K9AcS10P occupancywas
as high as 11.43 and 20.2 folds respectively; whereas H3K9me3 level
and H3K27me3 was very low, 0.63 and 0.06 folds only (Fig. 13 A, B).
3. Discussion
The CLU protein has a dual role in normal cellular function aswell as
in cancer development. Our results are in excellent support of this fact.
We have investigated the pattern of CLU (both sCLU and nCLU) expres-
sion and the epigenetic controlmechanisms involved in its regulation in
colon cancer cell lines. Previously, it has been reported that DNA
methylation is involved in CLU gene regulation in other cancer, namely,
prostate cancer [34]. In the present study, for the ﬁrst time, we have
demonstrated that the alteration of CLU expression in colon cancer
cells is controlled not by DNA methylation, but predominantly by
Fig. 9. nCLU, not sCLU, overexpression induced cell death. (Panel [I A]) nCLU and [I C] sCLUwere overexpressed in pIRES–nCLU transfected HCT cell line and the graphical representation of
relative [I B] nCLU and [I D] sCLU expression. (Panel [II]) Autophagy vacuoles formationwas increased in pIRES–nCLU–HCT15 than control vector pIRES–HCT15 cell linewhereas in pIRES–
sCLU–HCT15 cells autofagosome formation was near about same as pIRES–HCT15 cells (indicated by red staining and white arrow (magniﬁcation of images are 400×)). (Panel [III A])
Hoechst 33342 staining shows that condensed nucleus formation (indicated by white arrow) was increased in pIRES–nCLU–HCT15 and remains the same as pIRES–HCT15 cells. [B] Con-
densed nucleus formation was graphically represent (magniﬁcation of images is 200×) (n = 3 independent experiments). Scale bar = 20 μm.
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tion in CLU expression in rat colon tissue has been reported previously
[35,36]. The regulatory region of CLU promoter drives CLU expression
through binding of various signaling components and stress factors in
prostate cancer [32,37–40]. The best known epigenetic mechanisms
are DNA methylation of CpG islands and post-translational modiﬁca-
tions of the histone tails. Epigenetic mechanisms precisely have driven
the tissue speciﬁcity favoring asymmetric gene expression of an organ-
ism having the same set of genes comprising the unique genome andvarying epigenomes. Whereas, the cancer genome is widely varying
and variation is extensively unpredictable from cancer to cancers, and
so also the case with the cancer epigenome.
Hence, we have investigated the expression pattern of CLU protein
in FFPE cancer and non-cancerous tissue samples and found CLU
expression in all types of tissue samples analyzed in this paper. Howev-
er, only non-carcinogenic tissue samples show the expression of nCLU
(Fig. 1, A, AII). According to previous research, nCLU is expressed in
stress-induced cells [6]. The non-carcinogenic tumor does not have
Fig. 10.DNAmethylation analyses. (Panel [I A]) University of California Santa Cruz (UCSC) genome browser viewof CLU promoter region inCLU upstreamregion, [I B] promoter region and
[I C, D] distribution of CpG island. The two-headed arrows of [I C] point towards the region that was analyzed by bisulﬁte sequencing. Panel [II] bioinformatical analysis of promoter DNA
methylation and CLU expression in clinical colon cancer samples fromhttp://methhc.mbc.nctu.edu.tw/php/index.phpdatabase. It shows that CLU expression is promoter DNAmethylation
independent. (Panel [III]) Results of bisulﬁte genomic DNA sequencing covering the 20 CpG sites on CLU CGI of (A) HCT15 and (B) COLO205. Open squares indicate that CpG sites are
unmethylated; ﬁlled squares indicate CpG site methylation.
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is subjected to stress conditions. nCLUoverexpression leads to induction
of apoptosis in unhealthy/abnormal cells. But in primary andmetastasis
cancer tissue samples instead of nCLU, sCLU expression prevailed,
which is responsible for pro-survival signal (Fig. 1, B, C, D and CII).
CLU expression analyses in FFPE colon cancer tissue samples illustrate
a role for sCLU in colon cancer progression. This observation makes us
curious to decipher the molecular mechanism of CLU isoform
expression.
Accordingly, we proceededwith experiments for evaluating the CLU
expression in COLO-205 (Duke's type D, distantmetastasis) and HCT-15
(Duke's type C, lymph node metastasis) cell lines upon treatment with
four different epigenetic modulators and found higher expression of
CLU mRNA (Fig. 2). Highest mRNA expression is seen with TSA treat-
ment in the case of HCT15 cells and with TSA and SFN treatment in
the case of COLO205 cells (Fig. 2). Increase in CLU mRNA level after
epigenetic modulator treatment indicates that CLU expression is con-
trolled by epigenetic modiﬁcations in colon cancer cell lines. Increased
CLU expression after AZA (DNMT inhibitor) treatment preliminarily
indicated the involvement of DNA methylation in regulation of CLU
expression; however, later results (compare the results of Figs. 10, 11
& 12; also, see the discussion below) resolved the fact that CLU gene is
not directly regulated by DNA CGI methylation. Further, induction of
CLU expression on treatment with TSA and SFN (HDAC inhibitors)
makes it clear that not only DNA methylation modulators, but alsohistone acetylation modulators play a signiﬁcant role in CLU expression
in colon cancer (Fig. 2) But a complicated scenario appeared when we
treated the cells with SAM (methyl group donor). In many previous
studies, SAM was proportionately linked with increased DNA methyla-
tion with reduced gene expression. On the contrary, our results
implicated enhancement of CLUmRNAexpression after SAM treatment.
Moreover, SAM treatment does not cause potential cell growth inhibi-
tion (our previous observation). So, SAM may possibly be involved
with isoform speciﬁc CLU expression involving a mechanism linked to
differential histone methylation. After protein level analysis it becomes
distinctly clear that CLU gene was modulated vigorously by epigenetic
modiﬁers/drugs and expression was dramatically increased (Fig. 3
panels I, II and Fig. 4). AZA, TSA and SFN treatment increased both
sCLU as well as nCLU expression in comparison to untreated cells.
Highest nCLU protein expression is observed in TSA treated HCT15
cells, which is in correlation with highest mRNA expression level
(Fig. 4 panels I and II, Table 2). However, only sCLU, but not nCLU
expression is increased in SAM (20 μM) treated HCT15 cells (Fig. 4
panels I and II). This indicates that SAM is involved in cell survival rather
than cell death. In addition, SAM mediated epigenetic modulation
induces sCLU expression.
As reported previously that prolong AZA treatment efﬁciently
induces loss of DNAmethylation, we proceeded with 4 day contentious
AZA treatment. Treatments of cells with high dose of AZA for 24 h and
with low dose of AZA for prolong time increase nCLU expression in
Fig. 11. Histone modiﬁcation analyses. Histone posttranslational modiﬁcations in CGI promoter region of CLU (panel [I]) alignment of the sequence which was analyzed by bisulﬁte
sequencing and ChIP primers. (Panel [II-A]) PCR analysis of CLU promoter was shown H3K4me3, H3K9me3, H3K27me3 and H3K9AcS10 occupancy in HCT15 and COLO205. Where
mouse IgG precipitated DNA used as negative control. PCR analysis only shows the occupancy of histone marks in the promoter region. Fold enrichment analysis was done by RT-PCR
analysis. [B] RT-PCR analysis of H3K4me3, H3K9me3, H3K27me3 and H3K9AcS10 occupancy in CLU promoter of HCT15 and COLO205. The % Input for each ChIP fraction has been calcu-
lated by % Input = 2 (-ΔCt [normalized ChIP]) equation. Where mouse IgG precipitated DNA used as negative control. (mean ± s.e., n = 3 independent experiments). P b 0.05.
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highest CLU isoform expression (Fig. 5). This result is consistent with
both the ways; i.e., treatment with high concentration for short time,
24 h and treatment with low concentration for prolonged time, 96 h.
CLU is a stress induced protein. Treatment with epigenetic modulator
induces stress in cancer cell lines. So, CLU expression even controlled
by stress factors there must be epigenetic alteration or chromatin
remodeling behind it. Also, in order to distinguish whether the changes
in expression of CLU is solely due to cytotoxicity caused by the drugs
used or whether the drugs are responsible for epigenetically controlling
the expression, we performed a control set of experiments using Ara-C.
Cell lines were treated with Ara-C [41] in low and high (IC50) dose
(Fig. 6). It is apparent from the results depicted in Fig. 6, although
nCLU expression increases at IC50 of Ara-C, however the nCLU expres-
sion is much higher in AZA, TSA and SFN treated cells. This result clearly
depicted that although stress is a factor of nCLUexpression in epigenetic
modulator treated cells but epigenetic alteration is one of the key
regulators of CLU isoform expression in colon cancer.
To elucidate the association of epigenetic modulators in apopto-
sis induction, we analyzed chromatin condensation. In chromatincondensation assay, Hoechst 33342 stained nuclei are highly observed
in AZA, TSA and SFN but not in SAM treated cells in both cell lines
(Fig. 7 panels I and II). Also, the percentage of condensed nuclei is
found to be higher in the case of TSA treated cells (Fig. 7 panel III). Not
only chromatin condensation but also autophagy vacuole formation
was induced by AZA, TSA and SFN treatment HCT15 and CLO205 cell
which is a clear indicator of autophagy mediated cell death induction
(Fig. 8). The above analysis demonstrates that both cell death induction
and nCLU expression are highest in TSA treated cells, and lowest in SAM
treated cells. This explains a possible correlation between nCLU overex-
pression and cell death. Our hypothesis was conﬁrmed after nCLU and
sCLU overexpression. Previously it was reported that sCLU overexpres-
sion is associated with increase of cancer growth and chemoresistant
[7,37,42]. The pIRES–nCLU transfected HCT15 cells undergo very rapid
death and not pIRES–sCLU transfected HCT15 cells remain healthy.
Condensed nuclei and autophagy formation was drastically increase in
pIRES–nCLU HCT15 whereas pIRES–sCLU HCT15 cell does not show
signiﬁcant increase in cell death (Fig. 9). This conﬁrms that AZA, TSA
and SFN mediated growth inhibition is linked with nCLU overexpres-
sion in colon cancer.
Fig. 12. Histone modiﬁcation analyses of CLU promoter in LNCaP cells. (Panel [I A]) Western blot analysis of sCLU and nCLU expression in HCT15, COLO205 and LNCaP cell lines,
and [B] relative protein expression was represented graphically (mean ± S.D., n = 3). P b 0.05. Relative protein expression level was analyzed by ImageJ software and the nCLU
and sCLU levels are expressed in terms of band intensity. Beta actin is used as reference protein conﬁrming equal loading (n = 3 independent experiments, mean ± S.D.).
P b 0.05. (Panel [II]) PCR analysis of CLU promoter was shown H3K4me3, H3K9me3 and H3K9AcS10 occupancy in LNCaP cells. Mouse IgG precipitated DNA used as negative
control. [III] RT-PCR analysis of H3K4me3, H3K4me2, H3K9me3 and H3K9AcS10 occupancy in CLU promoter. The % Input for each ChIP fraction has been calculated by %
Input = 2 (-ΔCt [normalized ChIP]) equation. Where mouse IgG precipitated DNA used as negative control. (mean ± S.D., n = 2). P b 0.05.
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with different epigenetic modulator treatments and signiﬁcance of
nCLU expression in colon cancer cell death. To analyze the precise
epigenetic control mechanisms involved in different isoform expres-
sion, we proceeded with DNA methylation and ChIP analysis. Previous
studies on colon cancer illustrated that promoter CpG island and
CpG island shore methylation play important role in modulating multi-
ple gene expression [43,44]. Bioinformatics analysis reveals that
CLU expression in clinical colon cancer samples is promoter DNAFig. 13. Histone modiﬁcation analyses after TSA treatment. Chip analysis of CLU promoter re
H3K9me3, H3K27me3 and H3K9AcS10 occupancy in HCT15. [B] RT-PCR analysis of H3K4m
HCT15. The % Input for each ChIP fraction has been calculated by % Input = 2 (-ΔCt [normalized Ch
n = 3 independent experiments). P b 0.05.methylation independent (Fig. 10 panel II). Herein, our study shows
that a total of 19 CpG sites are in unmethylated state out of 20 CpG
sites of CLU promoter CGI in HCT15 and COLO205 cells (Fig. 10 panel
II A, B); whereas all the 20 CpG sites were in unmethylated state in
the case of AZA, TSA and SFN treated cells (Fig. 10 panel II A, B).
Unmethylated promoter region is permissible for gene expression [44].
So, unmethylated promoters of CLU in AZA, TSA and SFN treated cells
are related to elevated expression of both sCLU and nCLU (Figs. 3, 4
and 10, panel II A, B). Highest CLU expression in the case of TSA maygion in TSA treated HCT15 cell. [A] PCR analysis of CLU promoter was shown H3K4me3,
e3, H3K9me3, H3K27me3 and H3K9AcS10 occupancy in CLU promoter of TSA treated
IP]) equation. Where mouse IgG precipitated DNA used as negative control. (mean ± s.e.,
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of histone acetylation because of inhibition of HDACs by TSA [21,45].
When we analyzed the DNA methylation and the sCLU expression
level of SAM treated cells, both DNA methylation and the sCLU expres-
sion are found to be increased, but the extent of nCLU expression is neg-
ligible. SAM treatment increases methylation level from 1 to 4 only in
the promoter region, and that was not sufﬁcient to repress sCLU
(Figs. 3 and 4). SAM treatment affects global methylation status of a
cell and precisely the DNA and histone methylation. In this case SAM
treatment is responsible for nCLU downregulation. Why SAM induced
chromatin methylation modulation does not induce the nCLU expres-
sion is not clear from DNA-methylation analyses. sCLU and nCLU are
splice variants, perhaps some speciﬁc splicing factor/s modulated by
histone acetylation modiﬁcations are involved in this process, since
TSA triggers highest nCLU expression (Figs. 4 and 13).
To explore whether there is any histone modiﬁcations associated
with reduced CLU expression in metastasis colon cancer cell line we
have analyzed H3K4me3, H3K9me3, H3K27me3 and H3K9AcS10p
enrichment in CLU promoter region. H3K4me3 and H3K9AcS10p
are active marks, associated with activation of transcription [46,47].
H3K9me3 and H3K27me3 [47,48] enrichment in the promoter region
of gene leads to gene repression [31,49]. It has been widely known
that while H3K4me3 and H3K9AcS10p are associated with establish-
ment of euchromatin and transcriptional elongation, H3K9 and
H3K27me3 events participate in many repressive transcriptional
programs such as X chromosome inactivation and polycomb proteins
mediated speciﬁc gene silencing [50]. Our data on ChIP-RT analysis
reveals that H3K9me3 and H3K27me3 levels are higher than the other
two modiﬁcations in the promoter region of CLU (Fig. 9 panel II B).
But the H3K27me3 enrichment was highest among all those three
histone tags (Fig. 9 panel II B). Nevertheless, higher enrichment of
H3K9me3 and H3K27me3 in the promoter region of CLU is the reason
of lower expression of CLU in untreated colon cancer cell lines. Results
of our experiments clearly depicts similar expression pattern of nCLU
and sCLU on both methylated promoter region of CLU in LNCaP cell
line as well as non-methylated promoter region of CLU in HCT15 and
COLO205 cell lines (Fig. 12). However, we observed an increased level
of H3K9me3 and H3K27me3 deposition rather than H3K4me3,
H3K9acS10p at promoter region of CLU in both DNA methylated and
unmethylated conditions. This certainly depicts that histone modiﬁca-
tion plays a decisive role in expression of nCLU. TSA treated HCT15
cell analysis also conﬁrms the above idea as TSA treated cell shows
highest H3K4me3 and H3K9AcS10p enrichment in CLU promoter
(Fig. 13). Compiling the above results, our study conﬁrms that, not the
DNA methylation, rather histone modiﬁcations, including H3K4me3,
H3K9me3, H3K27me3 and H3K9AcS10p indeed have a signiﬁcant role
in CLU isoform expression in colon cancer. Our ﬁnding also reveals an
interesting path for regulation of expression of CLU isoforms. Large
body of evidence establishes a role for higher-order chromatin organi-
zation and dynamics in pre-mRNA splicing, and it is very reasonable
that modiﬁcations of histone, especially modiﬁcation of histone H3,
act in concert with these mechanisms [51–54]. Considering previous
information and our ﬁndings, we propose that the epigenetic memory
contained in histone modiﬁcation patterns is not only used to deter-
mine the level of activity of a gene but also transmit information to
establish, propagate, and regulate alternative splicing patterns during
disease progression such as colon cancer. Herein, we have demonstrat-
ed the involvement of H3K4me3, H3K9me3, H3K27me3 and
H3K9AcS10p in nCLU expression. nCLU expression was associated
with decreased H3K9me3 and H3K27me3 and increased H3K4me3,
and H3K9AcS10p levels in colon cancer cell lines. In 2007, Sims
et al. demonstrated that methylated H3K4 facilitates the bridging of
spliceosomal components which helps in pre-mRNA maturation and
alternative splicing [54]. Therefore, the enrichment of H3K4me3 and
H3K9AcS10p marks may inﬂuence the RNA polymerase II elongation
rate, chromatin remodeler and may help in expression of nCLU splicevariant. A more detailed analysis of pre-mRNA splicing of gene
transcripts co-transcriptionally (44) with expressive histone marks, re-
lated enzymes and connector proteins may unveil this enigma for CLU
and similar genes having alternatively spliced isoforms.
4. Conclusion
Clusterin is important for cellular homeostasis; however, aberrant
expression is frequent in cancer. H3K4me3 and H3K9AcS10P enrich-
ment are associated with nCLU overexpression and cell growth inhibi-
tion in colon cancer. H3K9me3 and H3K27me3 enrichment
downregulates nCLU and ectopic expression of nCLU induces cell
death. nCLU and sCLU expression is differentially regulated by histone
3 modiﬁcations and not by DNA methylation.
5. Materials and methods
5.1. Tissue samples and immunohistochemistry
55 formalin-ﬁxed parafﬁn-embedded (FFPE) colon cancer tissue
samples were collected from Drs. Tribedi & Roy Diagnostic Laborato-
ry (Kolkata, India). FFPE specimens were sliced into 0.5 μm and
subjected to antigen retrieval with Tris–EDTA buffer, endogenous
peroxidase blocking and rinsed with Tris-buffered saline (TBS) con-
taining 0.025% Triton X-100 (TBS-T). Goat anti-CLU antibody
(1:5000) (Santa Cruz Biotech) was used as primary antibody and
anti-goat (1:500) (Santa Cruz Biotech) was used as secondary anti-
body. After overnight incubation with anti-CLU antibody at 4 °C,
the specimens were rinsed with TBS and incubated at room temper-
ature for 1 h with secondary antibody. After rinsing with TBS, all
specimens were color-developed with 3,3′-diaminobenzidine
tetrahydrochloride (Sigma).
5.2. Cell culture
Colon cancer cell lines HCT15, COLO205 and LNCaP were obtained
from the National Centre for Cell Sciences, Pune (NCCS) and cell bank
conﬁrmed the authentication of cell lines. HCT15, COLO205 and LNCaP
cell lines were cultured in RPMI-1640 medium supplemented with
10% fetal calf serum and penicillin (100 unit/ml) streptomycin
(0.1 mg/ml). COLO205 and LNCaP was additionally supplemented
with 1 mM HEPES-buffer. Stock solutions of 5-aza-2′-deoxycytidine
(AZA) (Sigma), trichostatin A (TSA) (Sigma) and sulforaphane (SFN)
(Sigma), and cytosine arabinoside (Ara-C) (Sigma) were dissolved in
dimethylsulfoxide (DMSO) and S-adenosylmethionine (SAM) was
dissolved in sterile water. Stock solutions were further diluted in
medium prior to use.
Cellswere harvested by trypsinization and cell numberswere count-
ed by a hemocytometer and the number of living cells was calculated by
Trypan blue staining (0.2% v/v). 1 × 105 cells were seeded into each
60 mm dish followed by treatment with appropriate concentration of
drugs on next day.
5.3. Expression vectors and generation of stable clones
Full-length human nCLU expressing pIRES–nCLU vector and pIRES
vector (obtained Prof Paul B Fisher, VCU, USA), pIRES–sCLU vector and
pIRES vector (obtained from Prof S. Bettuzzi, University of Parma,
Italy). HCT15 cells were transfected with pIRES–hyg (as control) and
pIRES–nCLU. After transfection, cells were cultured in RPMI 1640
media supplemented with 10% FBS and 380 ug/ml of hygromycin B. In
brief, we prepared a kill curve using differentiation concentration of
hygromycin B for HCT15. 380 μg/ml of hygromycin B was selected
from the kill curve for future analysis. 5 × 105 HCT15 cells were seeded
in 6 well plates. 70% conﬂuent cells were transfected with lipid DNA
complex in opti-MEM medium [2.5 μg vector DNA was transfected
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cells were culture in RPMI 1640 medium supplemented with 10% FBS
and 380 μg/ml of hygromycin B. After one week culture we used the
pool of cells which survived the selection procedure for further experi-
ments [7].
5.4. RNA extraction and quantitative reverse-transcription (qRT)-PCR
The RT-PCR techniques have been previously described. Total RNA
was extracted with TRI Reagent (Sigma) for RT-PCR analysis. HCT-15
cells were treated with sublethal dosages of AZA 25 μM, TSA 180 nM,
SFN 18 μM, and SAM 20 μM and COLO-205 cells were treated with sub-
lethal dosages of AZA19 μM, TSA 155nM, SFN 17 μM, and SAM20 μMfor
24 h. After treatment for a required time total cellular RNA was
extracted with TRI Reagent (Sigma) according to the manufacturer's
instructions. qRT-PCR was performed using 1 μg of total RNA, RevertAid
First Strand cDNA Synthesis Kit (Thermo Scientiﬁc) and SYBR® Green
JumpStart™ Taq ReadyMix in the Realplex4 Eppendorf system. The
mRNA level was normalized to beta actin (elongation factor 1-α) [55].
The primer sequences for CLU ampliﬁcation were 5′-AAGAAAGAGGAT
GCCCTAAATGAG-3′ and 5′-TTCATGCAGGTCTGTTTCAGG-3′ (producing
a fragment of 130 bp). Beta actin was used as an internal control and
primer sequence was 5′-CTGGAACGGTGAAGGTGACA-3′ and 5′-AAGG
GACTTCCTGTAACAACGCA-3′ (producing a fragment of 141 bp).
5.5. Immunocytochemistry
Immunocytochemistry was performed as per our previous protocol
with some modiﬁcations [56–58]. In brief, colon cancer cell line, HCT-
15 was grown on glass cover slips and treated with above mentioned
concentrations of AZA, SAM, TSA, and SFN for 24 h. In brief, treated
cells were ﬁxed by ice cold methanol and were permeabilized by
0.25% Triton X-100 in PBS. Cells were incubated with 1% BSA in PBST
for 30 min to block unspeciﬁc binding of the antibodies. The endoge-
nous peroxidase activity was blocked by incubation with 5% H2O2 in
methanol for 20 min followed by incubation in primary antibody
overnight at 4 °C. The cells were then washed with PBS and incubated
with HRP-conjugated anti-goat secondary antibody (Santa Cruz
Biotech) for 1 h followed by another wash. Finally, reactions were
visualized after incubation with DAB (substrate and chromogen) and
counterstain with Mayer's hematoxylin. For negative control, cells
were incubated overnight with dilution buffer (no primary antibody)
[56].
5.6. Western blot analysis
Cells were grown up to 80–85% conﬂuency and harvested by scrap-
ping. Cellular proteins were extracted with lysis buffer (RIPA buffer,
Sigma) containing cocktail of protease inhibitors (Sigma). Equal
amounts of protein extract (50 μg) from each lysate were resolved
using SDS-polyacrylamide gel and electroblotted to PVDF membranes
(Millipore). Protein containing membranes were blocked with 5%
skimmed milk in 0.1% Tween 20 in Tris-buffered saline. Then mem-
branes were incubated overnight at 4 °C with goat anti-CLU (1:1000)
(Santa Cruz Biotech) and mouse monoclonal beta actin (1:400) (Santa
Cruz Biotech) antibodies. The membranes were then developed with
peroxidase-labeled secondary antibodies, anti-goat (1:5000) (Santa
Cruz Biotech) and anti-mouse (1:5000) (sigma) using SuperSignal
West Femto Chemiluminescent Substrate (Thermo Scientiﬁc). β-Actin
protein levels were used as a control for adequacy of equal protein
loading. All western blot experiments were carried out in triplicates.
5.7. Methylation speciﬁc PCR and bisulﬁte genomic DNA sequencing
CLU promoter DNA methylation was analyzed bioinformatically
from http://methhc.mbc.nctu.edu.tw/php/index.php database.Genomic DNA was isolated from treated cells by phenol chloroform
method. 2 μg of genomic DNA was bisulﬁte converted by EpiTect Bi-
sulﬁte Kit (Qiagen) according to the manufacturer's instructions.
Bisulﬁte-treated DNA was then used as template in PCR reactions
for PCR analysis. For bisulﬁte genomic DNA sequencing, 5′-GGGTTG
GTTGTAAATTTGTATGATT-3′ (sense) and 5′-TCCTATACTCTCTTCTCC
AACACAAA-3′ (antisense) were used to amplify (producing a frag-
ment of 413 bp with annealing at 55 °C) the region located at 5′ of
CLU promoter CGI region.
5.8. Chromatin immunoprecipitation (ChIP) assay
ChIP was performed with H3K4me3 rabbit anti-human polyclonal
antibody (Invitrogen) using an Imprint Chromatin Immunoprecipita-
tion Kit (Sigma) according to the manufacturer's instructions. Conven-
tional and real-time PCR techniques were used to analyze ChIP DNA.
For RT-PCR (Realplex4 Eppendorf) analysis SYBR® Green JumpStart™
Taq ReadyMix (Sigma) was used. 2 μl sonicated DNA was used for PCR
analysis with PCR condition 95 °C for 2 min, followed by 40 cycles of
95 °C for 20 s alternating with 55 °C for 30 s annealing and 72 °C exten-
sion for 30 s. CLU5′-GCATCATCACCACGAATAGC-3′ (sense) and 5′-GTGT
AATGTGAAGGTTAAGGTCAG-3′ (antisense) (producing a fragment of
198 bp) and GAPDH 5′ CAATTCCCCATCTCAGTCGT 3′ (sense) 5′ TAGT
AGCCGGGCCCTACTTT 3′ (antisense) (producing a fragment of 246 bp)
were ampliﬁed for analysis. Anti-mouse IgG precipitated DNA was
used as template for negative control. Input DNA (1%)was used for nor-
malization. % Input was calculated by using the formulas:
ΔCt normalized ChIP½  ¼ Ct ChIP½ − ðCt Input½ 
log2Input Dilution FactorÞ;
% Input ¼ 2 ðΔCt ½normalizedChIPÞ:
Where, Input Dilution Factor = (fraction of the inputchromatin
saved)-1. The default Input fraction is 1% which is a dilution factor of
100 or 6.644 cycles (i.e. log2 of 100). Thus, subtract 6.644 from the Ct
value of the 1% Input sample as mentioned in the equation. Where,
Input Dilution Factor = (fraction of the input chromatin saved)-1. The
default Input fraction is 1% which is a dilution factor of 100 or 6.644 cy-
cles (i.e. log2 of 100). Thus, subtract 6.644 from the Ct value of the 1%
Input sample as mentioned in the equation.
5.9. Chromatin condensation assay
After treatment with epigenetic modulators, cells were stained with
Hoechst 33342 (1mg/ml, Invitrogen) followed by incubation for 10min
at 37 °C and then images were taken under an Epi-ﬂuorescent micro-
scope (Olympus IX71). Condensed nucleus was counted against total
number of nucleus in the ﬁeld, and the percentage of apoptotic nuclei
was calculated and plotted graphically [59]. Only adherent cells of
COLO205 were analyzed by this analysis.
5.10. Detection and quantiﬁcation of autophagic cells by staining with
acridine orange
As a marker of autophagy, the volume of the cellular acidic com-
partments was visualized by acridine orange staining [60]. Cells
were seeded in six well tissue culture dishes and treated with the
drugs/epigenetic modulators as described above for the cell viability
study. 72 h following initial treatment, cells were incubated with
medium containing 1 μg/ml acridine orange (Invitrogen A3568) for
15 min. The acridine orange was then removed and cells were
washed once with PBS followed by addition of fresh media, and
then ﬂuorescent micrographs were taken using an Olympus inverted
ﬂuorescence microscope. All images presented are at the same
magniﬁcation.
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Statistical analysis was performed using the Student's t test by SPSS
software. All data for statistical analysis were calculated as mean ±
standard error. Differences were analyzed for signiﬁcance using one
way ANOVA. A probability value of 0.05 or less was considered
signiﬁcant.
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